Business Context and Reporting Period
This Form 6-K filing by Alcon, Inc. covers the month of November 2002. The report primarily addresses a voluntary product recall of the SKBM Microkeratome, a device acquired through the purchase of Summit-Autonomous Technologies, Inc.
Key Financial Metrics
- Product Sales: Year-to-date SKBM sales for 2002 totaled $3 million.
- Sales Contribution: SKBM sales represented approximately 0.1% of estimated total worldwide sales for 2002.
- Units in Market: Approximately 350 units are currently in the worldwide market.
- Anticipated Charge: Alcon expects an after-tax charge of approximately $15 million in the fourth quarter of 2002.
- Charge Composition: The charge includes estimated recall costs and the termination of the SKBM product line.
Material Changes and Unusual Items
The primary material event is the voluntary recall of the SKBM Microkeratome due to complaints that the applanation glass on the handpiece could loosen or become misaligned. This defect could result in corneal flaps being made at an undesired depth, potentially causing patient injury. Consequently, Alcon is terminating the product line and incurring a significant one-time charge.
Guidance, Outlook, and Risks
- 2002 Guidance: Management reaffirmed prior guidance for adjusted earnings per share for the fourth quarter and fiscal year, explicitly excluding the impact of the recall and other previously reported one-time items.
- 2003 Guidance: Management confirmed sales and earnings guidance for 2003, citing the company's diversified portfolio and the negligible contribution of the SKBM to total sales.
- Risks and Contingencies: Potential risks include litigation related to the recall, recall costs exceeding estimates, government regulatory actions, negative impacts on sales of other products, and broader market factors such as currency fluctuations and reimbursement changes.
Investor Verification Checklist
- Verify the final magnitude of the $15 million after-tax charge in the Q4 2002 earnings report.
- Monitor for any litigation settlements or regulatory fines arising from the SKBM recall.
- Confirm that the recall has not negatively impacted sales of Alcon's other ophthalmic products.
- Review subsequent filings to ensure 2003 sales and earnings guidance remains on track despite the recall.